## The causal relationship between cathepsins and multiple sclerosis : a mendelian randomization study

- Haining Lin<sup>1</sup>, Yuqing Shi<sup>1</sup>, Huazhong Xiong<sup>2</sup>, Dongyi Wang<sup>1</sup>, Shilei Wang<sup>1</sup>, Hailan Kang<sup>1</sup>, ZiXu 1
- Wang<sup>1</sup>,Zeyu Wang<sup>1\*</sup> and Jixiang Ren<sup>1,3\*</sup> 2
- 3 <sup>1</sup> Changchun University of Chinese Medicine, Changchun, China
- 4 <sup>2</sup> Prevention and Treatment Center, Affiliated Hospital to Changchun University of Chinese
- Medicine, Changchun, China 5
- 6 <sup>3</sup>First Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China
- 7 \* Corresponding authors
- 8 E-mail addresses: renjx2003@163.com (J. Ren)
- 9 E-mail addresses: zeyu781022@163.com (Z. Wang)
- 10 These authors contributed equally to this work.
- 11
- 12
- 13
- 14
- 15
- 16
- 17

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 18 Abstract

19	Background: Multiple sclerosis (MS) is a chronic autoimmune neurodegenerative
20	disease. Although some evidence indicates the potential involvement of cathepsins in
21	the MS process, the precise nature of this involvement remains uncertain. The
22	objective of this study was to ascertain whether there is a causal relationship between
23	cathepsins and MS.
24	Methods: This study aimed to examine the relationship between nine cathepsins and
25	MS, incorporating heterogeneity and sensitivity analyses into the study design. The
26	MR study was reported according to the STROBE-MR checklist.
27	<b>Results:</b> The MR analysis revealed a causal relationship between cathepsin H and MS
28	(IVW: P=0.036, OR=1.095, 95% CI=1.006-1.192); and an inverse causal relationship
29	between cathepsin E and MS (IVW: P=0.031, OR=1.043, 95% CI=1.004-1.083).
30	Conclusion: Genetically predicted risk of developing MS was associated with
31	increased cathepsin H, whereas elevated cathepsin E was associated with developing
32	MS, and their causal relationships were both unidirectional.
33	Keywords: Mendelian randomization, Multiple sclerosis, Cathepsin,
34	Demyelination,Nervous system disease.
35	
36	
37	

#### 38 Introduction

Multiple sclerosis (MS) is a chronic inflammatory illness caused by the immune 39 system, characterized by neurodegeneration and demyelination[1].MS has the 40 potential to result in a reduction in the quality of life of those affected, with the 41 possibility of further complications such as disability. This is due to the fact that MS 42 can manifest itself in neurological symptoms. The incidence and prevalence of MS are 43 increasing annually[2].In addition to several well-defined environmental factors. 44 Furthermore, numerous genes have been identified that, to a moderate extent, increase 45 disease susceptibility.[3]. Autoimmune activity against myelin components is thought 46 to be the primary process underlying the pathology of MS[4], including significant 47 infiltration of activated leukocytes into the central nervous system(CNS) via the 48 blood-brain barrier and processing and presentation of self-antigens 49 by antigen-presenting cells.[4, 5]. 50

An imbalance between protein hydrolysis and protein synthesis is a key factor in the 51 development of CNS diseases. Consequently, the study of protein degradation 52 pathways is of great importance in understanding the underlying pathology of these 53 diseases[6].Cathepsins are involved in a number of cellular processes, including cell 54 55 signalling, autophagy, and the transformation of proteins and lipids. They are primarily responsible for the metabolic degradation of peptides and proteins within 56 lysosomes[7, 8]. Some evidence suggests that in patients with MS, enzymatic 57 activities of the proteasome are enhanced in the central nervous system.[9].Cathepsins 58 can be classified into three categories: cysteine cathepsins (cathepsin B, C, L, etc.), 59

60 serine cathepsins (cathepsin G), and aspartate cathepsins (cathepsin D and E)[10]. Furthermore, there is a strong correlation between the activity of tissue proteases and 61 62 the progression of neurodegenerative diseases[11, 12]. In immune cells, cathepsin S and cathepsin L play a pivotal role in the processing of antigenic peptides and the 63 presentation of antigens by histocompatibility complex class II molecules. They are 64 also involved in the progressive catabolism of integral membrane proteins, which are 65 encoded by invariant chains and are expressed on the surface of antigen-presenting 66 cells[13-15]. The invasive and migratory properties of certain cathepsins [16, 17]may 67 68 be attributed to their capacity to maintain activity and degrade extracellular matrix (ECM) components, including laminin, and collagen, at physiological pH 69 values[18]. Given that protein hydrolytic degradation constitutes a pivotal process in 70 71 demyelination during MS, with the potential to precipitate neurodegeneration, cathepsins have been demonstrated to cleave myelin basic proteins, thereby exerting a 72 pivotal role in disease progression[19]. 73

74 In previous studies, although there is some evidence that cathepsins are involved in the process of MS, there is a lack of clear causality between cathepsins and MS, we 75 used.Mendelian randomisation (MR) analysis, which combines data 76 from genome-wide association studies (GWAS), is a statistical method used to determine 77 the causal relationship between exposures and outcomes[20].MR analyses have been 78 used more widely to assess possible causality between exposures and outcomes 79 because of the effectiveness of MR in reducing confounding bias and preventing 80 reverse causation, advantages that are based on the inability of the disease to alter the 81

82 genotypes in the germ line.

83	The goal of this study was to investigate the relationship between nine cathepsins and
84	MS, as identified through a large-scale genome-wide association study (GWAS),
85	through a comprehensive analysis of the genetic variants associated with them. This
86	was accomplished through the utilisation of a two-sample bidirectional MR approach,
87	which yielded insightful findings that significantly advanced the comprehension of
88	the underlying causal relationship between cathepsins and MS.

#### 89 Materials and methods

#### 90 Data sources

The gene detection levels of cathepsin B, E, F, G, H, L2, O, S, and Z (a total of nine types of cathepsins) were obtained from the INTERVAL study. The data can be accessed publicly via the following website: https://gwas.mrcieu.ac.uk. The sample size of this study is 3,301, and the participants are of European ethnicity[21].The INTERVAL study has been approved by the National Research Ethics Service in the United States, with approval number 11/EE/0538.

97 The International Classification of Diseases, Eleventh Revision code (ICD-11) for MS 98 is 8A40. The disease is defined as an inflammatory demyelinating disease 99 characterised by episodic neurological dysfunction in at least two central nervous 100 system regions (brain, spinal cord, and optic nerves) at different times and in different 101 spaces (different sites of lesions). The diagnostic criteria follow the 2017 version of 102 the McDonald diagnostic criteria [22]. The GWAS data for MS were obtained from

the publicly available GWAS database (https://gwas.mrcieu.ac.uk/), GWAS number ieu-b-18, which analysed the genetic data of 47,429 individuals. A total of 68,374 control subjects and 1,000 individuals with MS were included in the study, which aimed to create a reference atlas of the genetic structure of MS in the European population. The study involved both male and female subjects, and the number of single-nucleotide polymorphisms (SNPs) identified was 6,304,359 [23].

To prevent the introduction of bias and avoid data overlap, the sample data for cathepsins and MS were obtained from independent GWAS databases. No additional ethical approval or licence is required for the study, as all studies undergo review and approval by the relevant institutional ethics review committee and informed written consent is obtained from each participant.

#### 114 Study design and selection of IVs

The study methodology was in accordance with the STROBE-MR list [24], and we conducted a two-sample bidirectional MR study using publicly available GWAS summary data. The MR analyses were based on three key assumptions [25], the details of which are shown in Fig. 1, and we performed MR analyses and reverse MR analyses of cathepsins and MS, respectively.

120

Fig1.Flowchart of MR analysis. Three key assumptions of MR analysis: (1) IV must
be strictly related to the exposure factor; (2) IV must be independent of confounders
between the exposure factor and the outcome; and (3) IV will not influence the
outcome due to factors other than the exposure factor.

125

The following methods were employed to identify single-nucleotide polymorphisms 126 127 (SNPs) associated with exposure factors, with the objective of ensuring the reliability and accuracy of the results. SNPs with robust associations (p-value significance 128 threshold of less than  $5 \times 10^{-6}$ ) were treated as IVs. Additionally, those with 129 strand-balanced SNPs ( $r_2 = 0.001$ , genetic distance = 1000 kb) were excluded to 130 eliminate any potential bond disequilibrium[24]. To evaluate the potential for weak 131 instrumental bias, the F-statistic was employed to assess the weak IV bias of the 132 selected IVs[26]. 133

134

#### 135 MR analysis

The study was analysed using the TwoSampleMR (version 0.5.6) package in R 136 137 (version 4.4.1), and MR analyses were performed to estimate the overall effect of the selected SNPs on MS. The following MR methods were employed: Egger, Weighted 138 median, Inverse variance weighted, Simple mode and Weighted mode, with the 139 objective of verifying the consistency of the results[27]. Subsequently, inverse MR 140 analysis was conducted using the aforementioned MR methods. The odd ratio (OR) 141 was found to be statistically significant at the 95% confidence level with a two-sided 142 significance test, with P < 0.05. 143

144 The MR Egger intercept was employed for the purpose of detecting horizontal

pleiotropy. In the event that the intercept was found to be statistically significant (P < P

- 146 0.05), it was necessary to consider the reliability of the results. The Cochran's Q
- statistic was utilised for the assessment of heterogeneity (P < 0.05), while funnel plots

148	were employed for the purpose of The results are illustrated. The MR-PRESSO
149	outlier test and the estimated calibration values were applied to remove horizontal
150	pleiotropy, which can be used to exclude aberrant SNPs. The generation of forest
151	plots in the study enabled a visual assessment of the robustness of the results after
152	SNP removal by the leave-one-out method.

#### 153 **Results**

#### 154 **IV selection**

The present investigation utilised genetic variants from the INTERVAL study to examine cathepsins for MS from the GWAS database. Our bidirectional MR analyses identified multiple SNPs as IVs for each cathepsin and MS disease status, with a genome-wide significance threshold of  $P < 5 \times 10^{-6}$ . The F-statistic for each selected IV exceeded 10, indicating no weak IV bias.

#### **Results of the main MR analyses**

A two-sample MR analysis was conducted to evaluate the impact of cathepsins on MS, employing a range of data analysis techniques, including MR Egger, weighted median, inverse variance weighted, simple mode, and weighted mode. Of these approaches, the inverse variance weighted method is regarded as the most reliable for data analysis, particularly in instances where directed pleiotropy is absent. This method is frequently employed in meta-analyses of the effects of multiple genetic variants.

167

168 The findings of the two-sample MR analysis examining the relationship between

169	cathepsins and MS are illustrated in Figure 2. Additionally, a reverse MR analysis
170	investigating the reverse association between MS and cathepsins is presented in
171	Figure 3. All positive results ( $P > 0.05$ ) are presented in Table 1 for the reader's
172	convenience. The analysis indicates a causal relationship between cathepsin H and
173	MS, as well as a reverse causal relationship between cathepsin E and MS. Specifically,
174	elevated cathepsin H may be associated with an increased risk of developing MS
175	(IVW: P=0.036, OR=1.095, 95% CI=1.006-1.19). Furthermore, elevated cathepsin E
176	may be associated with the development of MS (IVW: P=0.031, OR=1.043, 95%
177	CI=1.004-1.083).
178	Furthermore, the Cochran Q test was employed to ascertain the extent of
179	heterogeneity between the SNPs. No evidence of heterogeneity or pleiotropy in
180	positive causality was identified ( $P > 0.05$ ), as evidenced by the resulting P-values and
181	MR-Egger intercepts (Table 1). The leave-one-out method analysis additionally
182	validated the robustness of the positive results, as illustrated in Figure 4.
183 184	
185	Fig2, MR results of the causal relationship between cathepsins and MS, OR, odds
186	ratio; CI, confidence interval.
187	
188	Fig3, MR results of inverse causality between cathepsins and MS, OR, odds ratio;
189	CI, confidence interval.
190	
191	

#### 192 Table 1 Mendelian randomisation analysis with positive results

It is made available unde	er a <mark>CC-B</mark>	Y 4.0 International license .
---------------------------	------------------------	-------------------------------

			NSN	NSN		Cochra	nn Q test	MR Egger		
exposure	outcome	method	nethod pval P		or(95%CI)	Q-value	P-value	Intercept	P-value	
cathepsin H	multiple sclerosis	MR Egger	14	0.643	0.944(0.744-1.198)	16.484	0.170	0.028	0.217	
		Weighted median	14	0.001	1.198(1.082-1.327)					
		Inverse variance weighted	14	0.036	1.095(1.006-1.192)					
		Simple mode	14	0.091	1.204(0.987-1.468)					
		Weighted mode	14	0.015	1.201(1.056-1.366)					
multiple sclerosis	cathepsin E	MR Egger	86	0.249	1.036 (0.976-1.099)	96.771	0.161	0.001	0.779	
		Weighted median	86	0.118	1.048 (0.988-1.111)					
		Inverse variance weighted	86	0.031	1.043 (1.004-1.083)					
		Simple mode	86	0.231	1.078 (0.954-1.217)					
		Weighted mode	86	0.074	1.052 (0.996-1.112)					

193

194

#### 195 Fig4 Scatterplot and leave-one-out analysis of Mendelian randomised causality,

(a) MR analysis of cathepsin H versus MS (b) reverse MR analysis of cathepsin E
versus MS (c) sensitivity analysis of the leave-one-out method for cathepsin H versus
MS (d) sensitivity analysis of the leave-one-out method for reverse causality of
cathepsin E versus MS.

#### 200 **Discussion**

MS manifests itself as an autoimmune demyelinating and neurodegenerative disease of the central nervous system. The mechanism by which MS occurs has not been fully elucidated, and is widely believed to be due to an autoimmune attack on

myelin.Genetic and environmental factors are thought to play a role in triggering the 204 immune system's attack on myelin[28]. Cathepsins are associated with the 205 206 development of neurodegenerative and immunocompetent disorders and are usually correlated with pathological conditions [8, 29]. Evidence from relevant studies has 207 shown [30-33]that a variety of cysteine cathepsins are involved in the inflammatory 208 process of different diseases through different pathological mechanisms [34]. While 209 in autoimmune mechanisms, cathepsins play a major role in phagocytosis and 210 autophagy [35], cathepsins may exert an indirect regulatory effect on autophagy and a 211 212 direct influence on cellular homeostasis and inflammatory processes[36]. In addition, cathepsins play an immunological role in the cytoplasmic lysosol, nucleus or 213 extracellular space, e.g. The release of cathepsins from the cytoplasmic lysosome and 214 215 nucleus may occur via either controlled or uncontrolled lysosomal membrane permeabilisation, resulting in lysosomal-dependent cell death [37]Conversely, those 216 present in the extracellular space may be involved in the remodelling of the 217 extracellular matrix[10]. Thus cathepsins may be involved in the disease progression 218 of MS. 219

Our findings suggest that the pathogenesis of MS may be associated with elevated cathepsin H. Although there are fewer studies directly correlating cathepsin H with the pathogenesis of MS, the current mechanism in animal models is thought to be that defective cathepsin H impairs TLR3-mediated activation of IRF3 and the consequent secretion of IFN- $\beta$  by dendritic cells, leading to enhanced differentiation of Th1 cells, which leads to the early onset of experimental autoimmune encephalomyelitis (EAE,

an animal model of multiple sclerosis)[38]. However, demyelination is a characteristic 226 manifestation of MS, and myelin is essential for neuronal axonal function in the CNS, 227 228 whereas microglia regulate the growth and integrity of myelin in the CNS, and are required to maintain myelin integrity by preventing myelin degeneration [39], and 229 microglia are immune cells residing in the brain that are involved in tissue 230 maintenance and immunosurveillance[40]. Cathepsin H was detected in different 231 brain regions within activated microglia, and a related study showed that CatH was 232 significantly upregulated in microglia from mice injected intraperitoneally with 233 234 lipopolysaccharide, and that pro-inflammatory cytokines induced the release of CatH from microglia, with profound and deleterious effects on microglia activation and 235 neuronal survival[41]. Another study showed that cathepsin H expression was 236 237 increased in microglia at the site of injury in a hypoxic-ischemic mouse model, and that cathepsin H inhibited astrocyte proliferation by controlling TLR3/IRF3 signalling 238 and subsequent IFN-  $\beta$ secretion [42]. We therefore hypothesise that microglia 239 function may be a relevant mechanism for the causal relationship between cathepsin 240 H and the development of MS, however existing studies on the correlation between 241 cathepsin H and MS are insufficient. Further studies are required to gain a 242 comprehensive understanding of the relationship between the aforementioned 243 variables. The findings of the present MR analysis may serve as a valuable point of 244 reference for future investigations into the role of cathepsin H in MS. 245

In our findings, suffering from MS may lead to elevated cathepsin E. Althoughevidence that MS directly leads to elevated cathepsin E has not emerged from current

research advances, it is interesting to note that related studies have suggested that 248 cathepsin E may be associated with an underlying mechanism of MS-related pain [43]. 249 250 This study found that cathepsin E-deficient mice were resistant to mechanically abnormal pain in EAE and that cathepsin E contributes to mechanically abnormal pain 251 252 in EAE mice, however, this study could not confirm the relationship between cathepsin E and MS-related neuropathic pain, as EAE can be induced by a variety of 253 immunogenic peptides, and therefore further analyses are still required. Notably, in 254 the CNS, cathepsin E is expressed only in microglia[44], and microglia activation is a 255 256 key factor in the induction of mechanical abnormalities in pain[45]; Moreover, cathepsin E has been demonstrated to be a crucial mediator in major 257 histocompatibility complex class II-mediated antigen presentation in microglia [46]. 258 259 In conclusion, analysis of MR results suggests that suffering from MS may lead to elevated cathepsin E, and related studies suggest that this may be associated with pain 260 in the disease; however, there are fewer available findings on cathepsin E and MS, so 261 further in-depth studies are necessary, and our results may provide potential research 262 directions for future studies on MS-related pain and cathepsin E. 263

Our findings establish a causal relationship between a range of cathepsins and MS. By employing MR analysis, the data can be understood with greater reliability and accuracy, avoiding potential bias introduced by external factors. MR analysis is a method of analysing genetic variation. The results of the present study contribute to the discovery of the role of cathepsins in the progression of MS and provide further research with potential value. It is important to acknowledge the limitations of this

study. Firstly, it should be noted that the GWAS data used in this study were derived 270 from Europe only and therefore do not represent a generalisable sample of the wider 271 272 population. Consequently, further expansion of the study is still needed. Secondly, there is evidence to suggest that cathepsin B may be associated with MS. A clinical 273 274 observational study demonstrated an increase in cathepsin B activity in peripheral blood mononuclear cells of MS patients[47], while the use of cathepsin B inhibitors 275 resulted in a significant reduction in the severity of clinical scores in EAE mice 276 [48].However, despite these findings, we were unable to identify a genetic tool for the 277 278 cathepsin B correlation, which led to the exclusion of our results from the tissue causal analyses of cathepsin B and MS. Secondly, as MR analysis can only provide 279 evidence of potential causality and is unable to identify the specific biological 280 281 pathways involved, future studies should combine bioinformatics analyses with relevant experiments to elucidate and validate the underlying mechanisms. 282

#### 283 Conclusion

This study examined scathepsins and MS using a bidirectional MR approach and the findings provide suggestive evidence that genetically predicted risk of developing MS is associated with increased cathepsin H and elevated cathepsin E is associated with developing MS, and that they are both unidirectionally causally related, however, further intervention trials are needed to elucidate the underlying mechanisms.

#### **Data availability statement**

290 The original contributions from this study are included in the article. Additional data291 inquiries can be directed to the corresponding authors.

#### 292 Author contributions

293 Haining Lin: Investigation, Data curation, Writing - original draft, Writing -

review & editing. Yuqing Shi: Investigation, Data curation, Methodology. Huazhong

295 Xiong: Investigation, Data curation. Dongyi Wang: Investigation, Project

administration. Shilei Wang: Investigation, Validation. Hailan Kang: Investigation.

- 297 Zixu Wang: Investigation. Zeyu Wang:Writing review & editing.Jixiang Ren:
- 298 Conceptualization, Writing review & editing.

#### 299 Funding

300 This article received support from the Natural Science Foundation of Jilin Province

- 301 (No.YDZJ202301ZYTS184) and the Administration of Traditional Chinese Medicine
- 302 of Jilin Province (No.2023021).

#### 303 Acknowledgments

The authors are thankful to all participants and investigators who contributed andshared summary-level data on GWAS.

#### **306** Conflict of interest

307 The authors affirm that the research was conducted without any potential conflict of

308 interest arising from commercial or financial relationships.

#### References 309

310 1. Marcus R. What Multiple Sclerosis? Jama. 2022; 328(20): 2078. ls 311 https://doi.org/10.1001/jama.2022.14236 PMID: 36413229. 312 Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple 2. 313 Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014; 83(11): 314 1022-1024. https://doi.org/10.1212/wnl.0000000000000768 PMID: 25200713. 315 3. Dobson R, Giovannoni G. Multiple sclerosis - a review. Eur J Neurol. 2019; 26(1): 27-40. Epub 316 20181118. https://doi.org/10.1111/ene.13819 PMID: 30300457. 1502-1517. 317 4. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372(9648): 318 https://doi.org/10.1016/s0140-6736(08)61620-7 PMID: 18970977. 319 5. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? 320 Ann Neurol. 2009; 65(3): 239-248. https://doi.org/10.1002/ana.21640 PMID: 19334069. 321 Górska E, Tylicka M, Kamińska J, Hermanowicz A, Matuszczak E, Ołdak Ł, et al. 20S constitutive 6. 322 proteasome, 20S immunoproteasome, and cathepsin S are high-sensitivity and independent markers 323 of immunological activity in relapsing-remitting type of multiple sclerosis. J Neurochem. 2024. Epub 20240624. https://doi.org/10.1111/jnc.16165 PMID: 38923513. 324 325 Fonović M, Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim Biophys 7. 326 Acta. 2014; 1840(8): 2560-2570. Epub 20140327. https://doi.org/10.1016/j.bbagen.2014.03.017 PMID: 327 24680817. 328 8. Brix K, Dunkhorst A, Mayer K, Jordans S. Cysteine cathepsins: cellular roadmap to different 329 functions. Biochimie. 2008: 90(2): 194-207. Epub 20070806. 330 https://doi.org/10.1016/j.biochi.2007.07.024 PMID: 17825974. Minagar A, Ma W, Zhang X, Wang X, Zhang K, Alexander JS, et al. Plasma ubiquitin-proteasome 331 9. system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and 332 treatment with interferon-beta-1b. Neurol Res. 2012; 34(6): 611-618. Epub 20120616. 333 334 https://doi.org/10.1179/1743132812y.0000000055 PMID: 22709658. 335 10. Vidak E, Javoršek U, Vizovišek M, Turk B. Cysteine Cathepsins and their Extracellular Roles: 336 Shaping the Microenvironment. Cells. 2019; 8(3). Epub 20190320. 337 https://doi.org/10.3390/cells8030264 PMID: 30897858. 11. Ginsberg SD, Hemby SE, Lee VM, Eberwine JH, Trojanowski JQ. Expression profile of transcripts in 338 339 Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol. 2000: 48(1): 77-87. PMID: 10894219. 340 12. Moon HY, Becke A, Berron D, Becker B, Sah N, Benoni G, et al. Running-Induced Systemic 341 Cathepsin B Secretion Is Associated with Memory Function. Cell Metab. 2016; 24(2): 332-340. Epub 20160623. https://doi.org/10.1016/j.cmet.2016.05.025 PMID: 27345423. 342 343 13. Burster T, Beck A, Tolosa E, Schnorrer P, Weissert R, Reich M, et al. Differential processing of autoantigens in lysosomes from human monocyte-derived and peripheral blood dendritic cells. J 344 345 Immunol. 2005; 175(9): 5940-5949. https://doi.org/10.4049/jimmunol.175.9.5940 PMID: 16237087. 346 14. Zavasnik-Bergant T, Turk B. Cysteine proteases: destruction ability versus immunomodulation 347 capacity in immune cells. Biol Chem. 2007; 388(11): 1141-1149. https://doi.org/10.1515/bc.2007.144 348 PMID: 17976006. 349 **15.** Hsing LC, Rudensky AY. The lysosomal cysteine proteases in MHC class II antigen presentation. 350 Immunol Rev. 2005; 207: 229-241. <u>https://doi.org/10.1111/j.0105-2896.2005.00310.x</u> PMID: 351 16181340.

perpetuity. It is made available under a CC-BY 4.0 International license .

16. Flannery T, Gibson D, Mirakhur M, McQuaid S, Greenan C, Trimble A, et al. The clinical
significance of cathepsin S expression in human astrocytomas. Am J Pathol. 2003; 163(1): 175-182.
https://doi.org/10.1016/s0002-9440(10)63641-3 PMID: 12819022.

17. Gillet L, Roger S, Besson P, Lecaille F, Gore J, Bougnoux P, et al. Voltage-gated Sodium Channel 355 356 Activity Promotes Cysteine Cathepsin-dependent Invasiveness and Colony Growth of Human Cancer 357 Cells. Biol Chem. 2009; 284(13): 8680-8691. 20090128. Л Epub https://doi.org/10.1074/jbc.M806891200 PMID: 19176528. 358

**18.** Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in
cardiovascular disease. Faseb j. 2007; 21(12): 3029-3041. Epub 20070523.
https://doi.org/10.1096/fj.06-7924com PMID: 17522380.

362 19. Wilkinson RD, Williams R, Scott CJ, Burden RE. Cathepsin S: therapeutic, diagnostic, and
363 prognostic potential. Biol Chem. 2015; 396(8): 867-882. <u>https://doi.org/10.1515/hsz-2015-0114</u> PMID:
364 25872877.

365 20. Burgess S, Davey Smith G, Davies NM, Dudbridge F, Gill D, Glymour MM, et al. Guidelines for
 366 performing Mendelian randomization investigations: update for summer 2023. Wellcome Open Res.
 367 2019; 4: 186. Epub 20230804. https://doi.org/10.12688/wellcomeopenres.15555.3 PMID: 32760811.

368 21. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of the
369 human plasma proteome. Nature. 2018; 558(7708): 73-79. Epub 20180606.
370 https://doi.org/10.1038/s41586-018-0175-2 PMID: 29875488.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple
sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018; 17(2): 162-173. Epub
20171221. https://doi.org/10.1016/s1474-4422(17)30470-2 PMID: 29275977.

374 23. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in
 375 susceptibility. Science. 2019; 365(6460). <u>https://doi.org/10.1126/science.aav7188</u> PMID: 31604244.

376 24. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM, Swanson SA, et al.
377 Strengthening the Reporting of Observational Studies in Epidemiology Using Mendelian
378 Randomization: The STROBE-MR Statement. Jama. 2021; 326(16): 1614-1621.
379 https://doi.org/10.1001/jama.2021.18236 PMID: 34698778.

380 25. Gagliano Taliun SA, Evans DM. Ten simple rules for conducting a mendelian randomization study.
 381 PLoS Comput Biol. 2021; 17(8): e1009238. Epub 20210812.
 382 <u>https://doi.org/10.1371/journal.pcbi.1009238</u> PMID: 34383747.

Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization
 studies. Int J Epidemiol. 2011; 40(3): 755-764. Epub 20110316. <u>https://doi.org/10.1093/ije/dyr036</u>
 PMID: 21414999.

27. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian
 randomization analyses using summarized data. Int J Epidemiol. 2017; 46(6): 1734-1739.
 <u>https://doi.org/10.1093/ije/dyx034</u> PMID: 28398548.

389 28. McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and Treatment of Multiple Sclerosis: A
 390 Review. Jama. 2021; 325(8): 765-779. <u>https://doi.org/10.1001/jama.2020.26858</u> PMID: 33620411.

391 29. Kramer L, Turk D, Turk B. The Future of Cysteine Cathepsins in Disease Management. Trends
 392 Pharmacol Sci. 2017; 38(10): 873-898. Epub 20170628. <u>https://doi.org/10.1016/j.tips.2017.06.003</u>
 393 PMID: 28668224.

30. Hargreaves P, Daoudlarian D, Theron M, Kolb FA, Manchester Young M, Reis B, et al. Differential
 effects of specific cathepsin S inhibition in biocompartments from patients with primary Sjögren

- 396 syndrome. Arthritis Ther. 2019; 175. 20190718. Res 21(1): Epub 397 https://doi.org/10.1186/s13075-019-1955-2 PMID: 31319889.
- 398 31. Shen XB, Chen X, Zhang ZY, Wu FF, Liu XH. Cathepsin C inhibitors as anti-inflammatory drug 399 discovery: Challenges and opportunities. Eur J Med Chem. 2021; 225: 113818. Epub 20210903. 400 https://doi.org/10.1016/j.ejmech.2021.113818 PMID: 34492551.
- 401 32. Bouras M, Asehnoune K, Roquilly A. Immune modulation after traumatic brain injury. Front Med (Lausanne). 2022; 9: 995044. Epub 20221201. https://doi.org/10.3389/fmed.2022.995044 PMID: 402 403 36530909.
- 404 33. Nakanishi H. Microglial cathepsin B as a key driver of inflammatory brain diseases and brain 405 aging. Neural Regen Res. 2020; 15(1): 25-29. https://doi.org/10.4103/1673-5374.264444 PMID: 406 31535638.
- 407 34. Senjor E, Kos J, Nanut MP. Cysteine Cathepsins as Therapeutic Targets in Immune Regulation and 408 Immune Disorders. Biomedicines. 2023; 11(2). Epub 20230207. 409 https://doi.org/10.3390/biomedicines11020476 PMID: 36831012.
- 410 35. Randow F, MacMicking JD, James LC. Cellular self-defense: how cell-autonomous immunity 411 protects against pathogens. Science. 2013; 340(6133): 701-706. 412 https://doi.org/10.1126/science.1233028 PMID: 23661752.
- 413 36. Anes E, Pires D, Mandal M, Azevedo-Pereira JM. Spatial localization of cathepsins: Implications in 414 immune activation and resolution during infections. Front Immunol. 2022; 13: 955407. Epub 415 20220803. https://doi.org/10.3389/fimmu.2022.955407 PMID: 35990632.
- 416 37. Reinheckel T, Tholen M. Low-level lysosomal membrane permeabilization for limited release and 417 sublethal functions of cathepsin proteases in the cytosol and nucleus. FEBS Open Bio. 2022; 12(4): 418 694-707. Epub 20220309. https://doi.org/10.1002/2211-5463.13385 PMID: 35203107.
- 419 38. Okada R, Zhang X, Harada Y, Wu Z, Nakanishi H. Cathepsin H deficiency in mice induces excess 420 Th1 cell activation and early-onset of EAE though impairment of toll-like receptor 3 cascade. Inflamm 421 Res. 2018; 67(5): 371-374. Epub 20180222. https://doi.org/10.1007/s00011-018-1136-9 PMID: 422 29470604.
- 423 39. McNamara NB, Munro DAD, Bestard-Cuche N, Uyeda A, Bogie JFJ, Hoffmann A, et al. Microglia 424 regulate central nervous system myelin growth and integrity. Nature. 2023; 613(7942): 120-129. Epub 425 20221214. https://doi.org/10.1038/s41586-022-05534-y PMID: 36517604.
- 426 40. Ni J, Wu Z, Meng J, Saito T, Saido TC, Qing H, et al. An impaired intrinsic microglial clock system 427 induces neuroinflammatory alterations in the early stage of amyloid precursor protein knock-in 428 173. mouse brain. J Neuroinflammation. 2019; 16(1): Epub 20190830. 429 https://doi.org/10.1186/s12974-019-1562-9 PMID: 31470863.
- 41. Fan K, Li D, Zhang Y, Han C, Liang J, Hou C, et al. The induction of neuronal death by up-regulated 430 431 microglial cathepsin H in LPS-induced neuroinflammation. J Neuroinflammation. 2015; 12: 54. Epub 432 20150319. https://doi.org/10.1186/s12974-015-0268-x PMID: 25889123.
- 433 42. Ni J, Zhao J, Zhang X, Reinheckel T, Turk V, Nakanishi H. Cathepsin H deficiency decreases 434 hypoxia-ischemia-induced hippocampal atrophy in neonatal mice through attenuated TLR3/IFN-β 435 Neuroinflammation. 18(1): 176. 20210810. signaling. Т 2021; Epub 436 https://doi.org/10.1186/s12974-021-02227-7 PMID: 34376208.
- 437 43. Harada Y, Zhang J, Imari K, Yamasaki R, Ni J, Wu Z, et al. Cathepsin E in neutrophils contributes to 438 the generation of neuropathic pain in experimental autoimmune encephalomyelitis. Pain. 2019; 160(9): 2050-2062. https://doi.org/10.1097/j.pain.00000000001596 PMID: 31095099. 439

440 44. Chlabicz M, Gacko M, Worowska A, Lapiński R. Cathepsin E (EC 3.4.23.34)--a review. Folia 441 Histochem Cytobiol. 2011; 49(4): 547-557. https://doi.org/10.5603/fhc.2011.0078 PMID: 22252749.

442 45. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, et al. P2X4


443 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature. 2003; 424(6950): 444 778-783. https://doi.org/10.1038/nature01786 PMID: 12917686.

445 46. Nakanishi H. Microglial functions and proteases. Mol Neurobiol. 2003; 27(2): 163-176. https://doi.org/10.1385/mn:27:2:163 PMID: 12777686. 446

447 47. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis--prevalence and clinical 448 characteristics. Eur J Pain. 2005; 9(5): 531-542. Epub 20041222. 449 https://doi.org/10.1016/j.ejpain.2004.11.005 PMID: 16139182.

450 48. Ansari MA, Nadeem A, Alshammari MA, Attia SM, Bakheet SA, Khan MR, et al. Cathepsin B inhibitor alleviates Th1, Th17, and Th22 transcription factor signaling dysregulation in experimental 451 113997. 452 autoimmune encephalomyelitis. Exp Neurol. 2022; 351: Epub 20220202.

453 https://doi.org/10.1016/j.expneurol.2022.113997 PMID: 35122866.



exposure	method	NSNP	p	val			or(95%CI)
cathepsin B	MR Egger		7	0.263		•	0.879(0.719-1.074)
	Weighted median		7	0.170			0.945 (0.87-1.025)
	Inverse variance weighted		7	0.773			0.986 (0.894-1.087)
	Simple mode		7	0.672		- <b>-</b>	0.964 (0.821-1.133)
	Weighted mode		7	0.162			0.939 (0.870-1.015)
cathepsin E	MR Egger	(	6	0.941		- <b>-</b>	0.983 (0.640-1.510)
	Weighted median		6	0.760		- <b>-</b>	0.979(0.855-1.121)
medRxiv preprint	doi: https://doi.org/10.1101/2024.09.05.24313125; this version r	osted September 1	6, 202	4. The copyrigh	t holder for this	- <b>+</b>	0.984 (0.878-1.103)
preprint (which	doi: https://doi.org/10.1101/2024.09.05.24313125; this version p was not certified by peer review) is the author/funder, who have perpetuity. It is made available under a CC-BY 4.0 Inte	as granted medRxiv	6 lice	ense to display t	he preprint in	•	0.978(0.790-1.211)
	Weighted mode		6	0.841		•	0.979(0.806-1.189)
cathepsin F	MR Egger		7	0.499		•	1.090(0.865-1.374)
	Weighted median		7	0.756		- <b>•</b>	0.926 (0.902-1.078)
	Inverse variance weighted		7	0.617		•	0.981 (0.912-1.056)
	Simple mode		7	0.584		•	0.962(0.846-1.096)
	Weighted mode		7	0.997		•	1.000(0.901-1.111)
cathepsin G	MR Egger	:	5	0.503		•	1.328 (0.639-2.761)
	Weighted median		5	0.996		•	1.001(0.820-1.221)
	Inverse variance weighted	:	5	0.603		<b></b>	1.050 (0.874-1.260)
	Simple mode		5	0.611		•	0.910(0.651-1.272)
	Weighted mode		5	0.578		•	0.914(0.684-1.222)
cathepsin H	MR Egger	14	4	0.643		•	0.944(0.744-1.198)
	Weighted median	14		0.001		•	1.198(1.082-1.327)
	Inverse variance weighted	14		0.036		•	1.095(1.006-1.192)
	Simple mode	. 14		0.091		•	1.204 (0.987-1.468)
	Weighted mode	14		0.015		•	1.201 (1.056-1.366)
cathepsin L2	MR Egger		5	0.993		• <b>•</b>	0.998(0.664-1.499)
	Weighted median		5	0.869		• • • • • • • • • • • • • • • • • • •	1.012(0.877-1.169)
	Inverse variance weighted		5	0.828			1.013(0.899-1.143)
	Simple mode		5	0.778			1.029(0.855-1.238)
	Weighted mode		5	0.774			1.028 (0.861-1.228)
cathepsin 0	MR Egger		(	0.462		•	0.811(0.485-1.357)
	Weighted median		( 7	0.889			0.989(0.846-1.156)
	Inverse variance weighted		(	0.591			0.966 (0.852-1.095)
	Simple mode		( 7	0.982			0.997 (0.770-1.291)
	Weighted mode	0	( )	0.993			1.001 (0.785-1.277)
cathepsin S	MR Egger	23		0.619			0.979(0.900-1.064)
	Weighted median	23		0.362			0.968 (0.903-1.038)
	Inverse variance weighted	23		0.845			0.995(0.944-1.049)
	Simple mode	23		0.466			0.946 (0.817-1.095)
anthanain 7	Weighted mode	23		0.295			0.963(0.898-1.032)
cathepsin Z	MR Egger Weighted median		9	0.623			1.044(0.887-1.229) 1.004(0.022-1.002)
	Weighted median		9	0.931			1.004(0.922-1.092)
	Inverse variance weighted		9	0.596			0.981 (0.913-1.053)
	Simple mode Weighted mode		9	0.814			0.980(0.832-1.155) 1.007(0.919-1.103)
	Weighted mode	1	9	0.890	-1.000	1.000	1.007(0.919-1.103)

outcome		method		NSNP	pva	1					or(95%CI	)	
cathepsin	B	MR Egger		8	6 (	0.263	-		•		1.308 (0	. 974-1. 1	.06)
	,	Weighted median		8	6 (	0. 170	-		•		1.030 (0	. 968-1. 0	95)
		Inverse variance we	ighted	8	6 (	0.773	-		÷	_	1.008 (0	. 968-1. 0	)50)
		Simple mode		8	6 (	0.672	_		•	-	1.018 (0	. 897-1. 1	55)
	1	Weighted mode		8	6 (	0. 162	-		•		1.042 (0	. 982-1. 1	.05)
cathepsin	E	MR Egger		8	6 (	0. 249	-		•		1.036 (0	. 976-1. 0	(99
	1	Weighted median		8	6 (	0. 118	_		•		1.048 (0	. 988-1. 1	11)
medRxi	iv preprint doi: ht	Ln/yerg/0.1101/2024.09.05.2431312	i ghted	sted September	6, 2024.	031	t holder for this		•		1.043 (1	. 004-1. 0	83)
prepri	int (which was r	ps://doi.org/10.1101/2024.09.05.2431312 ot certified by peer review) is the author per It is made available under a	/funder, who has petuity.	s granted medRx	iv a licens	to display th	e preprint in		•		1.078 (0	. 954-1. 2	217)
	I	Weighted mode	CC-DT 4.0 Inten	8	6 (	0. 074	-		•		1.052 (0	. 996-1. 1	12)
cathepsin	F	MR Egger		8	6 (	0.794	-		<b>•</b>	_	1.007 (0	. 953-1. 0	65)
	I	Weighted median		8	6 (	). 999	-		<b>•</b>		1.000 (0	. 949-1. 0	)54)
		Inverse variance we	ighted	8	6 (	0. 695	-		÷	_	1.007 (0	. 972-1. 0	)44)
		Simple mode		8	6 (	0. 749	_		÷	_	0.983 (0	. 886-1. 0	91)
		Weighted mode		8	6 (	0. 953	-		÷	_	0.999 (0	. 951-1. 0	)48)
cathepsin	G	MR Egger		8	6 (	0. 339	-		•		1.030 (0	. 969-1. 0	95)
		Weighted median		8	6 (	0. 949	-		•	-	1.002 (0	. 946-1. 0	)61)
		Inverse variance we	ighted	8	6 (	0.567	-		•		0.988 (0	. 950-1. 0	)29)
		Simple mode		8	6 (	0. 927	_		•	-	1.006 (0	. 880-1. 1	50)
	1	Weighted mode		8	6 (	0. 565	-		•	_	1.017 (0	. 960-1. 0	)78)
cathepsin		MR Egger		8		0. 384	-		•	_	1.029 (0		
		Weighted median		8		0. 698	-		•	-	0.989 (0		
		Inverse variance we	ighted			0. 235	-		•	_	1.025 (0		
		Simple mode				0. 768	_		•	-	0.982 (0		
		Weighted mode				0. 493	-		•	_	1.021 (0		
cathepsin		MR Egger				0.406	-		•	-	0.975 (0		
		Weighted median				0. 727	_		•	_	1.011 (0		
		Inverse variance we	ighted			0.614	-		•	_	0.990 (0		
		Simple mode				0. 796	_		•	-	1.016 (0		
		Weighted mode				0. 749			•	_	0.990 (0		
cathepsin		MR Egger				0.872	_		•	-	1.005 (0		
		Weighted median				0. 338	_		•		1.027 (0		
		Inverse variance we	ighted			0. 701	_		•		1.008 (0		
		Simple mode				0. 537			•		0.963 (0		
		Weighted mode				0. 320	_		•		1.029 (0		
cathepsin		MR Egger				0. 132	_	(		-	0.958 (0		
		Weighted median				0. 179	_			-	0.962 (0		and the second se
		Inverse variance we	1ghted			0. 171	-		•	_	0.975 (0		
		Simple mode				0. 495	_				1.042 (0		
and have the		Weighted mode				0. 142	_		1		0.963 (0		
cathepsin		MR Egger				0.944	_		I	_	0.998 (0		
		Weighted median	1-1-1-1			0.808	_		T		0.993 (0		
		Inverse variance we	ighted			0.561	-		1		1.011 (0		
		Simple mode				0.750			1		0.981 (0		
		Weighted mode		8	6 (	0.445	-0. 500	0.500	1.500		0.972 (0	. 924-1. 0	35)
							V. 000	0.000	1.000				

